ipharmacenter Consulting services

Saudi Food and Drug Authority (SFDA) has approved the registration of Anktiva (nogapendekin alfa inbakicept) for selected bladder and lung cancer indications, introducing a new immunotherapy option for patients with limited treatment choices. Under the new authorization, Anktiva may be used for adult patients with metastatic non‑small cell lung cancer whose disease has progressed after standard systemic therapies, in combination with immune checkpoint inhibitors. SFDA has als

CVS Health has laid out a broad strategy to simplify how Americans use health insurance while tackling the rising cost of care and medicines. The company stated that it is focused on easing administrative burdens for clinicians, shifting payments toward value, and expanding the use of lower‑cost treatment options. Making utilization management less burdensome Aetna, the health insurance arm of CVS Health, reports that it now applies prior authorization requirements to fewer m

The US Food and Drug Administration has authorised a new under‑the‑skin version of the CD20xCD3 bispecific antibody mosunetuzumab for adults with relapsed or refractory follicular lymphoma after two or more previous systemic treatments. This subcutaneous regimen, known as Lunsumio VELO, received accelerated approval based on phase I/II data from the GO29781 trial, with continued approval potentially dependent on confirmation of clinical benefit in a follow‑up study. iPharmaCe